These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33559893)

  • 1. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
    Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
    Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
    Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis].
    Wang Y; Huang W; Wei N; Zeng X; Zhang J; Wang J; Wu L; Fu L; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):901-4. PubMed ID: 25339326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
    Chen L; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
    Meng G; Wang Y; Wang J; Wang Z
    Leuk Lymphoma; 2021 Apr; 62(4):854-860. PubMed ID: 33225788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
    Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
    Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.
    Pi Y; Wang J; Zhou H; Ye X; Sun X; Liu L; Pan X; Wang Z
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3033-3041. PubMed ID: 35852619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
    Zhou L; Liu Y; Wen Z; Yang S; Li M; Zhu Q; Qiu S; Gao Y; Wang H; Yuan Y; Zhang H; Chen C; Zeng W; Guan Z; Pan X
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3063-3074. PubMed ID: 32617699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.
    Yildiz H; Bailly S; Van Den Neste E; Yombi JC
    Ther Clin Risk Manag; 2021; 17():293-304. PubMed ID: 33888986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
    Huang Z; Xie J
    Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.
    Marsh RA; Jordan MB; Talano JA; Nichols KE; Kumar A; Naqvi A; Vaiselbuh SR;
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease.
    Jin Z; Wang Y; Wei N; Wang Z
    Ann Hematol; 2020 Jul; 99(7):1575-1581. PubMed ID: 32500223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
    Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
    Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement for etoposide in the initial treatment of Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Song Y; Wang Y; Wang Z
    Br J Haematol; 2019 Sep; 186(5):717-723. PubMed ID: 31115044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
    Choi CW; Paek CW; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
    J Korean Med Sci; 2002 Oct; 17(5):621-4. PubMed ID: 12378012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.